Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.03, $0.09 better than the analyst estimate of $0.94. Revenue for the quarter came in at $349.5 million versus the consensus estimate of $340.09 million.

Charles River Laboratorie sees FY2015 EPS of $3.69-$3.74, versus the consensus of $3.64.

James C. Foster, Chairman, President and Chief Executive Officer, said, “We are very pleased with our outstanding third-quarter results. On a consolidated basis, we delivered high single digit, constant-currency organic revenue growth, and a non-GAAP operating margin above our 20% target. Each of our business segments reported organic revenue growth and improved non-GAAP operating margins. These results demonstrate the strength of our unique portfolio, the success of our targeted sales strategies, and our initiatives to increase operating effectiveness and efficiency. We have differentiated ourselves from the competition, and are gaining market share because clients appreciate the value we bring to their research efforts and the emphasis we place on individualized service.”

“Based on our third-quarter results and our expectations for the fourth quarter, we are increasing our 2015 full-year revenue and non-GAAP earnings per share guidance. We now expect revenue growth in a range from 9.5% to 10% in constant currency, and non-GAAP earnings per share in a range from $3.69 to $3.74,” Mr. Foster concluded.

For earnings history and earnings-related data on Charles River Laboratorie (CRL) click here.